HL-085 + docetaxel

HL-085 + docetaxel is an experimental combination therapy consisting of HL-085, a selective, orally administered MEK1/2 inhibitor, and docetaxel, a well-established taxane chemotherapeutic agent. HL-085 (also called tunlametinib) inhibits MEK1 and to a lesser extent MEK2, leading to reduced downstream ERK phosphorylation and suppression of tumor cell growth and proliferation, particularly in cancers driven by RAS/RAF pathway mutations, such as NRAS-mutant melanoma[1][4]. Docetaxel stabilizes microtubules and prevents cell division, promoting apoptosis in dividing cells. The combination is under investigation to potentiate anti-tumor effects by targeting both cell signaling and cell division pathways. HL-085 was developed by Shanghai Kechow Pharma and has been evaluated for safety and efficacy in phase 1/2 studies in advanced melanoma[1][2][3][4].

Other names

tunlametinib + docetaxel